Liver surgery for advanced ovarian cancer: a systematic review of literature

Objective: To analyze the surgical treatment of liver metastases from advanced ovarian cancer (AOC) during either primary or interval debulking surgery (PDS or IDS). Data sources, methods of study selection: A systematic research of the literature was conducted in Scopus, PubMed/MEDLINE, ScienceDirect and the Cochrane Library, including observational prospective, retrospective studies, case series and case reports. Tabulation, integration and results: We collected data regarding study features, characteristics of the patients and of liver metastasis, the type of surgical treatment and postoperative morbidity. The type of liver surgery was described according to the terminology of Brisbane 2000 (TB2000). Ten articles were selected, and 61 patients were included, even though data was not complete for all of them. The weighted average age was 57 years old, and most women underwent PDS (n = 21/32 [66%]). The number of liver metastases was available only for 17 patients including 3 (18%) and 14 (82%) with multiple and single lesions, respectively. Metastasis from peritoneal seeding (peritoneal metastasis) was the most common type of lesion (n = 27/42 [64%]). Only in one study the authors declared the specialty of the surgeon performing the procedures (hepatobiliary). Two studies (n = 15) adopted the TB2000 and reported as follow: 47% wedge resections, 33% segmentectomies, 13% hemi-hepatectomies and 7% right-trisegmentectomy. Clavien-Dindo grade III or greater complications was 13% (n = 2/15). Conclusions: Liver resection is feasible during either PDS or IDS. Single lesion and peritoneal metastasis represent the most common conditions. Wedge liver resection is the most frequent procedure. Prognostic advantage is suggested after liver surgery especially for peritoneal metastasis.

Advanced ovarian cancer; Cytoreductive surgery; Liver metastases resection; Hepatic surgery

[1] Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. Journal of Clinical Oncology. 2002; 20: 1248–1259.

[2] Moore K, Colombo N, Scambia G, Kim B, Oaknin A, Friedlander M, et al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. The New England Journal of Medicine. 2018; 379: 2495–2505.

[3] Prat J. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. International Journal of Gynaecology and Obstetrics. 2014; 124: 1–5.

[4] Tozzi R, Traill Z, Garruto Campanile R, Ferrari F, Soleymani Majd H, Nieuwstad J, et al. Porta hepatis peritonectomy and hepato-celiac lymphadenectomy in patients with stage IIIC-IV ovarian cancer: Diagnostic pathway, surgical technique and outcomes. Gynecologic Oncology. 2016; 143: 35–39.

[5] Soleymani Majd H, Ferrari F, Manek S, Gubbala K, Campanile RG, Hardern K, et al. Diaphragmatic peritonectomy vs. full thickness resection with pleurectomy during Visceral-Peritoneal Debulking (VPD) in 100 consecutive patients with stage IIIC-IV ovarian cancer: a surgical-histological analysis. Gynecologic Oncology. 2016; 140: 430–435.

[6] Tozzi R, Ferrari F, Nieuwstad J, Campanile RG, Soleymani Majd H. Tozzi classification of diaphragmatic surgery in patients with stage IIIC–IV ovarian cancer based on surgical findings and complexity. Journal of Gynecologic Oncology. 2020; 31: e14.

[7] Güth U, Huang DJ, Bauer G, Stieger M, Wight E, Singer G. Metastatic patterns at autopsy in patients with ovarian carcinoma. Cancer. 2007; 110: 1272–1280.

[8] Soleymani Majd H, Ferrari F, Gubbala K, Campanile RG, Tozzi

R. Latest developments and techniques in gynaecological oncology surgery. Current Opinion in Obstetrics & Gynecology. 2015; 27: 291–296.

[9] Gadducci A, Tana R, Landoni F, Ferrari F, Peiretti M, Perrone F, et al. Analysis of failures and clinical outcome of advanced epithelial ovarian cancer in patients with microscopic residual disease at second-look reassessment following primary cytoreductive surgery and first-line platinum-based chemotherapy. European Journal of Gynaecological Oncology. 2013; 34: 213–217.

[10] Ferrari F, Ficarelli S, Forte S, Valenti G, Ardighieri L, Sartori E, et al. Extra-abdominal ovarian cancer presenting with breast metastases at diagnosis: Case report and literature review. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2020; 255: 211–221.

[11] Deng K, Yang C, Tan Q, Song W, Lu M, Zhao W, et al. Sites of distant metastases and overall survival in ovarian cancer: a study of 1481 patients. Gynecologic Oncology. 2018; 150: 460–465.

[12] Klein DA, Mann AK, Freeman AH, Liao C, Kapp DS, Chan JK. Chemotherapy alone for patients 75 years and older with epithelial ovarian cancer - is interval cytoreductive surgery still needed? American Journal of Obstetrics and Gynecology. 2020; 222: 170.e1–170.e11.

[13] Gasparri ML, Grandi G, Bolla D, Gloor B, Imboden S, Panici PB, et al. Hepatic resection during cytoreductive surgery for primary or recurrent epithelial ovarian cancer. Journal of Cancer Research and Clinical Oncology. 2016; 142: 1509– 1520. [12] Ferrari F, Forte S, Sbalzer N, Zizioli V, Mauri M, Maggi C, et al. Validation of an enhanced recovery after surgery protocol in gynecologic surgery: an Italian randomized study. American Journal of Obstetrics and Gynecology. 2020; 223: 543.e1–543.e14.

[15] Fagotti A, Ferrandina G, Vizzielli G, Fanfani F, Gallotta V, Chiantera V, et al. Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of perioperative outcome. European Journal of Cancer. 2016; 59: 22–33.

[16] Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. British Medical Journal. 2009; 339: b2535.

[17] Bacalbasa N, Dima S, Brasoveanu V, David L, Balescu I, Purnichescu-Purtan R, et al. Liver resection for ovarian cancer liver metastases as part of cytoreductive surgery is safe and may bring survival benefit. World Journal of Surgical Oncology. 2015; 13: 235.

[18] Strasberg SM, Belghiti J, Clavien P-A, Gadzijev E, Garden JO, Lau W-Y, et al. The Brisbane 2000 Terminology of Liver Anatomy and Resections. HPB. 2000; 2: 333–339.

[19] Dundr P, Gregová M, Němejcová K, Bártů M, Hájková N, Ho-jný J, et al. Ovarian mesonephric-like adenocarcinoma arising in serous borderline tumor: a case report with complex morphological and molecular analysis. Diagnostic Pathology. 2020; 15: 91.

[20] Luna-Abanto J, García Ruiz L, Laura Martinez J, Álvarez Larraondo M, Villoslada Terrones V. Liver Resection as Part of Cytoreductive Surgery for Ovarian Cancer. Journal of Gynecologic Surgery. 2020; 36: 70–75.

[21] Kato K, Katsuda T, Takeshima N. Cytoreduction of diaphragmatic metastasis from ovarian cancer with involvement of the liver using a ventral liver mobilization technique. Gynecologic Oncology. 2016; 140: 577–579.

[22] Bacalbaşa N, Balescu I, Dima S, Popescu I. Long-term Survivors after Liver Resection for Ovarian Cancer Liver Metastases. Anticancer Research. 2015; 35: 6919–6923.

[23] Neumann UP, Fotopoulou C, Schmeding M, Thelen A, Papanikolaou G, Braicu EI, et al. Clinical outcome of patients with advanced ovarian cancer after resection of liver metastases. Anticancer Research. 2012; 32: 4517–4521.

[24] Lim MC, Kang S, Lee KS, Han S, Park S, Seo S, et al. The clinical significance of hepatic parenchymal metastasis in patients with primary epithelial ovarian cancer. Gynecologic Oncology. 2009; 112: 28–34.

[25] Kollmar O, Moussavian MR, Richter S, Bolli M, Schilling MK. Surgery of liver metastasis in gynecological cancer - indication and results. Onkologie. 2008; 31: 375–379.

[26] Chalkiadakis GE, Lasithiotakis KG, Petrakis I, Kourousis C, Georgoulias V. Major hepatectomy and right hemicolectomy at the time of primary cytoreductive surgery for advanced ovarian cancer: report of a case. International Journal of Gynecological Cancer. 2005; 15: 1115–1119.

[27] Chi DS, Temkin SM, Abu-Rustum NR, Sabbatini P, Jarnagin WR, Blumgart LH. Major Hepatectomy at Interval Debulking for Stage IV Ovarian Carcinoma: a Case Report. Gynecologic Oncology. 2002; 87: 138–142.

[28] Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, et al. The Clavien-Dindo Classification of Surgical Complications: five-year experience. Annals of Surgery. 2009; 250: 187–196.

[29] Aletti GD, Eisenhauer EL, Santillan A, Axtell A, Aletti G, Holschneider C, et al. Identification of patient groups at high-est risk from traditional approach to ovarian cancer treatment. Gynecologic Oncology. 2011; 120: 23–28.

[30] Aletti GD, Dowdy SC, Podratz KC, Cliby WA. Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer. American Journal of Obstetrics and Gynecology. 2007; 197: 676.e1–

676. e7.

[31] Reuss A, du Bois A, Harter P, Fotopoulou C, Sehouli J, Aletti G, et al. TRUST: Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGO‐OVAR OP7). International Journal of Gynecologic Cancer. 2019; 29: 1327–1331.

[32] Harter P, Sehouli J, Reuss A, Hasenburg A, Scambia G, Cibula D, et al. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. a project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. International Journal of Gynecological Cancer. 2011; 21: 289–295.

[33] Coleman RL, Spirtos NM, Enserro D, Herzog TJ, Sabbatini P, Armstrong DK, et al. Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer. New England Journal of Medicine. 2019; 381: 1929–1939.

[34] Chi DS, McCaughty K, Diaz JP, Huh J, Schwabenbauer S, Hummer AJ, et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer. 2006; 106: 1933–1939.

[35] Du Bois A, Sehouli J, Vergote I, Ferron G, Reuss A, Meier W, et al. Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer: Final analysis of AGO DESKTOP III/ENGOT-ov20. Journal of Clinical Oncology. 2020; 38: 6000–6000.

[36] Zang R, Zhu J, Shi T, Liu J, Tu D, Yin S, et al. A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1/SGOG-OV2. Journal of Clinical Oncology. 2020; 38: 6001–6001.

[37] Gervais DA, Arellano RS, Mueller PR. Percutaneous radiofrequency ablation of ovarian cancer metastasis to the liver: indications, outcomes, and role in patient management. American Journal of Roentgenology. 2006; 187: 746–750.

[38] Gao W, Guo Z, Zhang X, Wang Y, Zhang W, Yang X, et al. Percutaneous cryoablation of ovarian cancer metastasis to the liver: initial experience in 13 patients. International Journal of Gynecological Cancer. 2015; 25: 802–808.

[39] Vogl TJ, Naguib NNN, Lehnert T, Nour-Eldin NA, Eichler K, Zangos S, et al. Initial experience with repetitive transarterial chemoembolization (TACE) as a third line treatment of ovarian cancer metastasis to the liver: indications, outcomes and role in patient’s management. Gynecologic Oncology. 2012; 124: 225–229.

[40] Starzl TE, Bell RH, Beart RW, Putnam CW. Hepatic trisegmen-tectomy and other liver resections. Surgery, Gynecology & Obstetrics. 1975; 141: 429–437.

[41] Strasberg SM. Nomenclature of hepatic anatomy and resections: a review of the Brisbane 2000 system. Journal of Hepato-Biliary-Pancreatic Surgery. 2005; 12: 351–355.